Entera Bio (ENTX)
(Delayed Data from NSDQ)
$2.02 USD
-0.06 (-2.88%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $2.02 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ENTX 2.02 -0.06(-2.88%)
Will ENTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ENTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ENTX
Entera Bio Ltd. (ENTX) Reports Q3 Loss, Tops Revenue Estimates
Are Medical Stocks Lagging Argenx (ARGX) This Year?
ENTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
ENTX & OPK Stock May Gain Following Positive PK/PD Research Data
Is Entera Bio (ENTX) Stock Outpacing Its Medical Peers This Year?
Is Entera Bio (ENTX) Outperforming Other Medical Stocks This Year?
Other News for ENTX
Entera Bio Receives FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 ...
Entera Bio (ENTX) Gains FDA Support for Phase 3 Osteoporosis Drug Study
Entera Bio receives FDA agreement on BMD as primary endpoint for EB613 study
Entera Bio (ENTX) Highlights Dual Action of EB613 at ASBMR 2025 | ENTX Stock News
Entera Bio announces data for EB613 to be presented at ASBMR 2025